[1]谢自勤,罗 赟,康信勇,等.左西孟旦治疗心力衰竭的临床疗效及对患者心功能及炎性反应的影响[J].医学信息,2024,37(22):110-113.[doi:10.3969/j.issn.1006-1959.2024.22.027]
　XIE Ziqin,LUO Yun,KANG Xinyong,et al.Clinical Efficacy of Levosimendan in the Treatment of Heart Failure and its Effect on Cardiac Function and Inflammatory Response in Patients with Heart Failure[J].Journal of Medical Information,2024,37(22):110-113.[doi:10.3969/j.issn.1006-1959.2024.22.027]
点击复制

左西孟旦治疗心力衰竭的临床疗效及对患者心功能及炎性反应的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年22期
页码:
110-113
栏目:
论著
出版日期:
2024-11-15

文章信息/Info

Title:
Clinical Efficacy of Levosimendan in the Treatment of Heart Failure and its Effect on Cardiac Function and Inflammatory Response in Patients with Heart Failure
文章编号:
1006-1959（2024）22-0110-04
作者:
谢自勤; 罗 赟; 康信勇; 华传仁
于都县人民医院电生理科，江西 于都 342300
Author(s):
XIE Ziqin; LUO Yun; KANG Xinyong; HUA Chuanren
Department of Electrophysiology,Yudu County People’s Hospital,Yudu 342300,Jiangxi,China
关键词:
心力衰竭; 左西孟旦; 心功能; 炎性反应; 抗心衰治疗; 强心剂
Keywords:
Heart failure; Levosimendan; Cardiac function; Inflammatory reaction; Anti-heart failure treatment; Cardiac stimulants
分类号:
R541.6
DOI:
10.3969/j.issn.1006-1959.2024.22.027
摘要:
目的 研究左西孟旦（LS）治疗心力衰竭（HF）的临床效果。方法 纳入2021年9月-2023年8月于都县人民医院收治的68例HF病例，行随机数字表法分为常规组（34例）与LS组（34例），常规组行常规抗心衰治疗，LS组在常规组基础上联合LS治疗，比较两组临床疗效、心功能指标[左室射血分数（LVEF）、二尖瓣舒张早期血流速度/舒张晚期血流速度（E/A）]、炎性反应因子[超敏C反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）]、6 min步行距离（6MWD）、心力衰竭症状状态问卷（SSQ-HF）评分。结果 LS组总有效率高于常规组（P＜0.05）。与治疗前相比，两组治疗后LVEF、E/A均有增大（P＜0.05），hs-CRP、TNF-α均有下降（P＜0.05），且LS组LVEF、E/A大于常规组（P＜0.05），hs-CRP、TNF-α低于常规组（P＜0.05）；与治疗前相比，两组治疗后1个月的6MWD结果均有提升，SSQ-HF评分均有下降（P＜0.05），且LS组6MWD结果大于常规组，SSQ-HF评分低于常规组（P＜0.05）。结论 左西孟旦治疗HF效果肯定，可改善患者心功能，下调机体炎性反应，缓解其心衰症状，值得临床应用。
Abstract:
Objective To investigate the clinical efficacy of levosimendan (LS) in the treatment of heart failure (HF).Methods From September 2021 to August 2023, 68 patients with HF admitted to Yudu County People’s Hospital were selected and divided into conventional group (34 patients) and LS group (34 patients) by random number table method. The conventional group was treated with conventional anti-heart failure treatment, and the LS group was treated with levosimendan on the basis of the control group. The clinical efficacy, cardiac function indexes [left ventricular ejection fraction (LVEF), mitral early diastolic blood flow velocity/late diastolic blood flow velocity (E/A)], inflammatory factors [high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α)], 6 min walking distance (6MWD), and heart failure symptom status questionnaire (SSQ-HF) scores were compared between the two groups.Results The total effective rate of the LS group was higher than that of the conventional group (P<0.05). Compared with before treatment, LVEF and E/A in the two groups increased after treatment (P<0.05), hs-CRP and TNF-α decreased (P<0.05), and LVEF and E/A in the LS group were higher than those in the conventional group (P<0.05), hs-CRP and TNF-α were lower than those in the conventional group (P<0.05). Compared with before treatment, the 6MWD result of the two groups was improved one month after treatment, and the SSQ-HF scores were decreased (P<0.05). The 6MWD result of the LS group was greater than those of the conventional group, and the SSQ-HF score was lower than that of the conventional group (P<0.05).Conclusion Levosimendan is effective in the treatment of HF. It can improve the cardiac function of patients, down-regulate the body’s inflammatory response, and relieve the symptoms of heart failure. It is worthy of clinical application.

参考文献/References:

[1]杨志绢,徐涛,钱明月.左西孟旦治疗老年急性失代偿性心力衰竭的效果[J].河北医药,2023,45(14):2149-2152.[2]谢飞,周芃.持续微泵注射左西孟旦治疗STEMI合并心力衰竭的临床研究[J].中西医结合心脑血管病杂志,2022,20(7):1261-1264.[3]晏露,赵智慧,赵青,等.左西孟旦治疗重症肺动脉高压合并右心衰竭患者的有效性和安全性观察[J].中国循环杂志,2022,37(3):239-242.[4]牛洁婷,马育霞,李艳光,等.左西孟旦联合新活素治疗顽固性心力衰竭的临床疗效[J].中国老年学杂志,2021,41(24):5489-5491.[5]Apostolo A,Vignati C,DELLA R,et al.Why Levosimendan Improves the Clinical Condition of Patients With Advanced Heart Failure: A Holistic Approach[J].Journal of Cardiac Failure,2022,28(3):509-514.[6]薛晨,周淑玲.传统药物联合左西孟旦治疗老年顽固性心力衰竭临床疗效分析[J].创伤与急危重病医学,2021,9(3):171-172,175. [7]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.[8]李喆,常凤军,白净.重复应用左西孟旦治疗老年顽固性心力衰竭的疗效[J].心血管康复医学杂志,2020,29(4):425-429.[9]翟云,杨柳,袁志敏,等.左西孟旦与多巴酚丁胺治疗充血性心力衰竭的效果及对脑钠肽、心功能的影响[J].解放军医药杂志,2020,32(8):24-27.[10]赵萍,张博,许杰.左西孟旦与冻干重组人脑利钠肽治疗顽固性心力衰竭的临床疗效[J].中国老年学杂志,2020,40(14):2921-2923.[11]杨飞,王少华,赵丽娜,等.静脉注射左西孟旦治疗晚期严重心力衰竭患者的疗效分析[J].中国急救医学,2018,38(8):706-710.[12]冯婧,鲁佳佳,赵琳.重组人脑利钠肽联合左西孟旦对老年急性失代偿性心力衰竭患者心功能和血清N末端B型脑钠肽前体及和肽素水平的影响[J].中国医药,2020,15(5):665-668.[13]康丽惠,牛永红,康林,等.左西孟旦联合血液超滤治疗顽固性心力衰竭患者的疗效观察[J].中国循证心血管医学杂志,2019,11(8):954-956.[14]孙飞,王海珠,刘丹丹,等.左西孟旦对老年急性心力衰竭患者心脏功能MACE事件及不良反应的影响[J].安徽医学,2019,40(6):621-624.[15]刘锦文,吴志光,严宪才.左西孟旦治疗老年急性心力衰竭的疗效及其对心功能、血清Gal-3及CPP水平的影响[J].心血管康复医学杂志,2019,28(1):61-65.[16]田青,郭庆,卫银芝,等.左西孟旦与冻干重组人脑利钠肽联合治疗老年心力衰竭对患者心脏功能和血流动力学水平影响[J].实用医学杂志,2019,35(3):452-455.[17]罗勤,金旗,柳志红,等.左西孟旦治疗重症肺动脉高压合并右心衰竭患者的临床观察[J].中国呼吸与危重监护杂志,2021,20(3):203-205.[18]陈忠宁,罗桂金,陈远博.左西孟旦治疗急性心力衰竭的疗效及安全性评价[J].中西医结合心脑血管病杂志,2018,16(21):3166-3168.[19]张倩,郭杨,魏路佳,等.左西孟旦对老年急性心肌梗死合并心力衰竭患者的临床疗效及安全性评价 [J].中国医药,2018,13(4):481-484.[20]陈雨,王伟红,李萍,等.老年缺血性心肌病心力衰竭采用左西孟旦联合曲美他嗪治疗的效果研究[J].河北医药,2018,40(13):1945-1948.[21]俞瑞群,王丹,吴晓蓉,等.左西孟旦治疗老年慢性心力衰竭急性加重患者的临床疗效[J].实用心脑肺血管病杂志,2018,26(5):88-90.[22]汪月奔,虞意华,龚仕金,等.左西孟旦治疗32例高龄重症心力衰竭患者的疗效与安全性[J].中华内科杂志,2020,59(6):433-438.

相似文献/References:

[1]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,31(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
　GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Journal of Medical Information,2018,31(22):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[2]程 林.重组人脑利钠肽用于重症急性心肌炎伴 心力衰竭患者治疗的临床研究[J].医学信息,2018,31(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
　CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Journal of Medical Information,2018,31(22):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[3]胡丽君.螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析[J].医学信息,2018,31(08):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
　HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Journal of Medical Information,2018,31(22):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
[4]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
　LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Journal of Medical Information,2018,31(22):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[5]何玲玲,程淑芬.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察[J].医学信息,2018,31(13):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
　HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Journal of Medical Information,2018,31(22):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
[6]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
　ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Journal of Medical Information,2018,31(22):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[7]施国富,吴春阳,施亚明,等.血浆脑钠肽对射血分数保留心力衰竭患者的诊断价值研究[J].医学信息,2018,31(16):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
　SHI Guo-fu,WU Chun-yang,SHI Ya-ming,et al.Diagnostic Value of Plasma Brain Natriuretic Peptide in Patients with Heart Failure Preserved by Ejection Fraction[J].Journal of Medical Information,2018,31(22):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
[8]李 宁,胡硕强.心脏再同步治疗心力衰竭的文献计量分析[J].医学信息,2018,31(19):79.[doi:10.3969/j.issn.1006-1959.2018.19.024]
　LI Ning,HU Shou-qiang.Bibliometric Analysis of Cardiac Resynchronization in the Treatment of Heart Failure[J].Journal of Medical Information,2018,31(22):79.[doi:10.3969/j.issn.1006-1959.2018.19.024]
[9]颜 琼,王 静,胡 聪.慢性心力衰竭患者半年内重返住院的调查分析与对策[J].医学信息,2018,31(20):173.[doi:10.3969/j.issn.1006-1959.2018.20.055]
　YAN Qiong,WANG Jing,HU Cong.Investigation and Countermeasures of Patients with Chronic Heart Failure Returning to Hospital within Half a Year[J].Journal of Medical Information,2018,31(22):173.[doi:10.3969/j.issn.1006-1959.2018.20.055]
[10]杨锦龙,刘 欢.甲状腺激素测定在高血压心力衰竭患者中的临床意义[J].医学信息,2018,31(22):96.[doi:10.3969/j.issn.1006-1959.2018.22.026]
　YANG Jin-long,LIU Huanc.Clinical Signifcance of Changes of Serum Thyroid Hormone Levels in Hypertensive Patients with Chronic Heart Failure[J].Journal of Medical Information,2018,31(22):96.[doi:10.3969/j.issn.1006-1959.2018.22.026]

更新日期/Last Update: 1900-01-01